Tags

Type your tag names separated by a space and hit enter

Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo.
Cancer Chemother Pharmacol. 2010 Jul; 66(2):277-85.CC

Abstract

PURPOSE

Inflammation plays a crucial role in the development of lung cancer. Accumulated studies have proved that non-steroidal anti-inflammatory drugs (NSAIDs) which block inflammation by their actions on arachidonic acid (AA) metabolism have a potential role in cancer chemotherapy and chemoprevention. The aim of our study was to investigate whether darbufelone, a novel anti-inflammatory drug, has anticancer effects in lung cancer.

METHODS

Human non-small cell lung cancer cell lines were treated with darbufelone at various doses and time points for analysis of cell viability, cell cycle, and apoptosis in vitro. The in vivo effect of darbufelone was assessed in Lewis lung carcinoma mice model.

RESULTS

Darbufelone inhibited the proliferation of non-small cell lung cancer cell lines in a dose-dependent manner, and induced cell cycle arrest at G0/G1 phase through up-regulation of p27 expression. Treatment with darbufelone also induced apoptosis by activating caspase-3 and caspase-8. Lewis lung carcinoma growth was also significantly inhibited by darbufelone treatment at daily dose of 80 mg/kg.

CONCLUSIONS

Taken together, these studies suggested that darbufelone, an anti-inflammation drug, might represent a novel therapeutic approach for lung cancer treatment.

Authors+Show Affiliations

Department of Pharmacology, China Pharmaceutical University, 24 Tong Jia Xiang, 210009, Nanjing, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20352217

Citation

Ye, Xiaolei, et al. "Darbufelone, a Novel Anti-inflammatory Drug, Induces Growth Inhibition of Lung Cancer Cells Both in Vitro and in Vivo." Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, 2010, pp. 277-85.
Ye X, Zhou W, Li Y, et al. Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo. Cancer Chemother Pharmacol. 2010;66(2):277-85.
Ye, X., Zhou, W., Li, Y., Sun, Y., Zhang, Y., Ji, H., & Lai, Y. (2010). Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 66(2), 277-85. https://doi.org/10.1007/s00280-009-1161-z
Ye X, et al. Darbufelone, a Novel Anti-inflammatory Drug, Induces Growth Inhibition of Lung Cancer Cells Both in Vitro and in Vivo. Cancer Chemother Pharmacol. 2010;66(2):277-85. PubMed PMID: 20352217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo. AU - Ye,Xiaolei, AU - Zhou,Wu, AU - Li,Yongqi, AU - Sun,Yihua, AU - Zhang,Yihua, AU - Ji,Hui, AU - Lai,Yisheng, Y1 - 2010/03/30/ PY - 2009/06/23/received PY - 2009/10/06/accepted PY - 2010/3/31/entrez PY - 2010/3/31/pubmed PY - 2010/6/5/medline SP - 277 EP - 85 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother Pharmacol VL - 66 IS - 2 N2 - PURPOSE: Inflammation plays a crucial role in the development of lung cancer. Accumulated studies have proved that non-steroidal anti-inflammatory drugs (NSAIDs) which block inflammation by their actions on arachidonic acid (AA) metabolism have a potential role in cancer chemotherapy and chemoprevention. The aim of our study was to investigate whether darbufelone, a novel anti-inflammatory drug, has anticancer effects in lung cancer. METHODS: Human non-small cell lung cancer cell lines were treated with darbufelone at various doses and time points for analysis of cell viability, cell cycle, and apoptosis in vitro. The in vivo effect of darbufelone was assessed in Lewis lung carcinoma mice model. RESULTS: Darbufelone inhibited the proliferation of non-small cell lung cancer cell lines in a dose-dependent manner, and induced cell cycle arrest at G0/G1 phase through up-regulation of p27 expression. Treatment with darbufelone also induced apoptosis by activating caspase-3 and caspase-8. Lewis lung carcinoma growth was also significantly inhibited by darbufelone treatment at daily dose of 80 mg/kg. CONCLUSIONS: Taken together, these studies suggested that darbufelone, an anti-inflammation drug, might represent a novel therapeutic approach for lung cancer treatment. SN - 1432-0843 UR - https://www.unboundmedicine.com/medline/citation/20352217/Darbufelone_a_novel_anti_inflammatory_drug_induces_growth_inhibition_of_lung_cancer_cells_both_in_vitro_and_in_vivo_ L2 - https://dx.doi.org/10.1007/s00280-009-1161-z DB - PRIME DP - Unbound Medicine ER -